In both research and clinical settings, the ability to identify which immune cells in a person’s body contribute to either cancer progression or clearance and their target specificity is of critical importance. Moreover, a more thorough understanding of the biological properties of T cells that correlate with clinical outcome is required and can help guide manufacturing processes that result in highly potent and durable anti-tumor CAR-T/TCR-T cells.
In this webinar, Dr. Anthony E. Zamora will introduce single cell, multiplex analysis using proteomic barcoding and optofluidic technologies, as well as present two case studies highlighting how these technologies can accelerate the identification and validation of neoantigens and cognate TCR sequences, identify unique cytokine secretion patterns associated with CAR-T effectiveness, as well as reveal functional differences in CAR-T attributed to manufacturing conditions.
Case Study 1: Identifying key tumor- and immune-centric parameters using streamlined single cell workflows to help guide the development and validation of engineered TCR-T cells for cancer.
Highlights include:
- Using antigen presenting beads to determine exchange rates and stability of cancer neoantigens across mutation types and to expand different clonotypes of neoepitope-specific CD8+ T cells.
- Determining differences in polyfunctionality between neoepitope-specific CD8+ T cells and validating functional responses of engineered TCR-T cells using optofluidic single cell technology.
Case Study 2: Single-cell analysis of bispecific CD20/CD19 CAR-T cells helps identify CAR T cells with favorable anti-tumor killing potential
We performed single-cell analysis to interrogate how different cytokine regimens used during manufacturing impacts the phenotype, secretory profile, and cytotoxic function of CAR T cells. Additional insight into how linking these parameters helps uncover the heterogenous nature of CAR T cell function and whether this may better correlate with clinical outcome. Key findings:
- Cytokine priming during manufacturing alters CAR-T cell antitumor function.
- Differences in CAR-T’s underlying biology, such as their phenotype, secretory profile, and rate of killing help shape their persistence and clinical efficacy.
